Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology Halle (Saale) / Munich, Germany, March 28 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon), a

#VVY Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology

www.stocktitan.net/news/VVY/vivoryon-therap...

Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent and pronounced treatment effect, further supporting plans to advance development in stage 3b/4 DKD

#VVY Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates

www.stocktitan.net/news/VVY/vivoryon-therap...

Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025 Compelling kidney function data from VIVIAD Phase 2b study presented in late-breaking poster at ASN kidney week, the world’s premier nephrology meeting VIVIAD

#VVY Vivoryon Therapeutics N.V. Presents Phase 2 Kidney Function and Biomarker Data at the American Society of Nephrology Kidney Week 2025

www.stocktitan.net/news/VVY/vivoryon-therap...

Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million Vivoryon Therapeutics (Euronext: VVY) completed a private placement on October 6, 2025, raising EUR 5.1 million by issuing 3,380,500 new ordinary shares at EUR 1.50 per share.The placement equals 12.9% dilution of existing share capital, raises shares outstanding to 29,614,337, and increases share capital from EUR 262,338.37 to EUR 296,143.37.Proceeds will fund near-term development of lead candidate varoglutamstat in diabetic kidney disease, support partnership negotiations, and provide a cash runway well into Q3 2026. New shares are expected to trade on Euronext Amsterdam on October 7, 2025 with delivery around October 9, 2025.

#VVY Vivoryon Therapeutics N.V. Successfully Completes Private Placement Raising EUR 5.1 Million

www.stocktitan.net/news/VVY/vivoryon-therap...

Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates Vivoryon Therapeutics N.V. (VVY) reported H1 2025 financial results and significant progress in their kidney disease program. Key highlights include compelling kidney function data from two Phase 2 studies (VIVIAD and VIVA-MIND), showing varoglutamstat's ability to improve eGFR values. The company secured a new U.S. patent for varoglutamstat extending protection through 2044.Financial results show a reduced net loss of EUR 5.5M compared to EUR 13.6M in H1 2024, with R&D expenses decreasing to EUR 2.8M from EUR 10.3M. Cash position stands at EUR 4.8M, expected to fund operations into January 2026. The company entered a EUR 15M Standby Equity Purchase Agreement with Yorkville Advisors and is actively seeking additional funding for planned Phase 2b DKD studies.Pre-clinical data revealed synergistic effects when combining varoglutamstat with SGLT-2 inhibitors, showing promising results in inflammation, fibrosis, and kidney function markers.

#VVY Vivoryon Therapeutics N.V. Reports H1 2025 Financial Results and Business Updates

www.stocktitan.net/news/VVY/vivoryon-therap...

Vivoryon Therapeutics Strengthens Leadership: New COO Joins Board, All Directors Reappointed Dr. Julia Neugebauer joins board as executive director while shareholders approve all agenda items. See complete leadership changes and strategic implications.

#VVY Vivoryon Therapeutics N.V. Reports Outcome of 2025 Annual General Meeting

www.stocktitan.net/news/VVY/vivoryon-therap...

Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress Vivoryon Therapeutics reported Q1 2025 financial results and operational progress, focusing on advancing varoglutamstat for kidney disease treatment. Key highlights include encouraging preclinical data showing synergistic effects when combining varoglutamstat with SGLT-2 inhibitors, and a new U.S. patent extending exclusivity through 2044. The company's net loss decreased to EUR 2.5M from EUR 9.3M year-over-year, with cash position at EUR 7.0M as of March 31, 2025. R&D expenses decreased to EUR 1.2M from EUR 7.4M due to clinical trial completions. Vivoryon secured a EUR 15M Standby Equity Purchase Agreement with Yorkville Advisors and expects current funding to last until January 2026. The company plans to initiate a Phase 2b study in diabetic kidney disease, subject to additional funding or partnership.

#VVY Vivoryon Therapeutics N.V. Q1 2025 Financial Results and Operational Progress

www.stocktitan.net/news/VVY/vivoryon-therap...

Phase 2 Clinical Trials Reveal Promising New Treatment for Diabetic Kidney Disease: Key Data Released at ERA 2025 Novel drug varoglutamstat demonstrates significant kidney function improvement in Phase 2 studies, with enhanced benefits for diabetic patients. See detailed trial results.

#VVY Vivoryon Therapeutics N.V. Presents Meta-analysis Data of VIVIAD and VIVA-MIND studies at ERA 2025

www.stocktitan.net/news/VVY/vivoryon-therap...

Major Patent Win: Vivoryon Secures 20+ Year Exclusivity for Revolutionary Kidney Disease Drug New US patent protects varoglutamstat's unique polymorph structure until 2044, expandable to 2049. Explore the drug's potential in kidney disease treatment. See development plans.

#VVY Vivoryon Therapeutics N.V. Expands Intellectual Property Portfolio with New U.S. Composition of Matter Patent Granted for Varoglutamstat

www.stocktitan.net/news/VVY/vivoryon-therap...

Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update Successful strategic shift towards a focus on inflammatory and fibrotic diseases, in particular on kidney disease Varoglutamstat Phase 2 program shows highly consistent, statistically significant and

#VVY Vivoryon Therapeutics N.V. Reports Full Year 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/VVY/vivoryon-therap...

Vivoryon Lands EUR 15M Equity Deal: Critical Funding Secured for Kidney Disease Drug Trial New equity purchase agreement fuels Vivoryon's Phase 2b kidney disease trial and VY2149 development. See how this strategic funding impacts pipeline advancement.

#VVY Vivoryon Therapeutics N.V. Signs Financing Agreement for up to EUR 15 Million

www.stocktitan.net/news/VVY/vivoryon-therap...

Can This Breakthrough Kidney Drug Transform Vivoryon's Future? Phase 2 Data Reveals Stunning 70% Response Rate Phase 2 studies demonstrate significant kidney function improvement with varoglutamstat as Vivoryon pivots focus to promising CKD treatment development.

#VVY Vivoryon Therapeutics N.V. Shares Highlights from Virtual R&D Update with KOL Speakers

www.stocktitan.net/news/VVY/vivoryon-therap...

Vivoryon's Varoglutamstat Shows Promising Kidney Function Improvements in Clinical Analysis Meta-analysis reveals significant eGFR improvements with varoglutamstat treatment, particularly effective in diabetic patients. Company strengthens patent portfolio and advances kidney disease pipeline.

#VVY Vivoryon Therapeutics N.V. Provides R&D-Update Further Strengthening Development Pipeline in Kidney Disease

www.stocktitan.net/news/VVY/vivoryon-therap...

Vivoryon's Varoglutamstat Shows Breakthrough Results in Kidney Disease Clinical Trials Phase 2 studies reveal significant kidney function improvements, with diabetic patients showing exceptional 8.2mL/min/1.73m2/year benefit. Company plans DKD expansion.

#VVY Vivoryon Therapeutics N.V. Reports Q3 2024 Results and Highlights Progress on Varoglutamstat in Kidney Disease

#investing #news #StockMarket

www.stocktitan.net/news/VVY/vivoryon-therap...